Evidence map›Paper›PMID 22855353›Full record

ReviewHeart failure reviews2013

Pericardial syndromes: an update after the ESC guidelines 2004.

Petar M Seferović, Arsen D Ristić, Ružica Maksimović, Dejan S Simeunović, Ivan Milinković, Jelena P Seferović Mitrović, Vladimir Kanjuh, Sabine Pankuweit, Bernhard Maisch

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 86 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Cardiac Tamponade After COVID-19 Vaccination.The Journal of emergency medicine · 2022
    Article
  6. The role ofScientific reports · 2020
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Multimodality imaging of pericardial disease.Current cardiology reports · 2015
    Review
  14. An expanding role for interleukin-1 blockade from gout to cancer.Molecular medicine (Cambridge, Mass.) · 2014
    Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Management of Malignant Pericardial Effusion.Journal of the advanced practitioner in oncology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Petar M SeferovićDepartment of Cardiology, Clinical Center of Serbia and Belgrade University School of Medicine, Koste Todorovića 8, 11000, Belgrade, Serbia. seferovic@med.bg.ac.rs
Arsen D Ristić
Ružica Maksimović
Dejan S Simeunović
Ivan Milinković
Jelena P Seferović Mitrović
Vladimir Kanjuh
Sabine Pankuweit
Bernhard Maisch
University of Belgrade · RSPhilipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite a myriad of causes, pericardial diseases present in few clinical syndromes. Acute pericarditis should be differentiated from aortic dissection, myocardial infarction, pneumonia/pleuritis, pulmonary embolism, pneumothorax, costochondritis, gastroesophageal reflux/neoplasm, and herpes zoster. High-risk features indicating hospitalization are: fever >38 °C, subacute onset, large effusion/tamponade, failure of non-steroidal anti-inflammatory drugs (NSAIDs), previous immunosuppression, trauma, anticoagulation, neoplasm, and myopericarditis. Treatment comprises 10-14-days NSAID plus 3 months colchicine (2 × 0.5 mg; 1 × 0.5 mg in patients <70 kg). Corticosteroids are avoided, except for autoimmunity, as they facilitate the recurrences. Echo-guided pericardiocentesis (±fluoroscopy) is indicated for tamponade and effusions >2 cm. Smaller effusions are drained if neoplastic, purulent or tuberculous etiology is suspected. In recurrent pericarditis, repeated testing for autoimmune and thyroid disease is appropriate. Pericardioscopy and pericardial/epicardial biopsy may clarify the etiology. Familial clustering was recently associated with tumor necrosis factor receptor-associated periodic syndrome (TNFRSF1A gene mutation). Treatment includes 10-14 days NSAIDs with colchicine 0.5 mg bid for up to 6 months. In non-responders, low-dose steroids, intrapericardial steroids, azathioprine, and cyclophosphamide can be tried. Successful management with interleukin-1 receptor antagonist (anakinra) was recently reported. Pericardiectomy remains the last option in >2 years severely symptomatic patients. In constriction, expansion of the heart is impaired by the rigid, chronically inflamed/thickened pericardium (no thickening ~20 %). Chest radiography, echocardiography, computerized tomography, magnetic resonance imaging, hemodynamics, and endomyocardial biopsy indicate the diagnosis. Pericardiectomy is the only treatment for permanent constriction. Predictors of poor survival are prior radiation, renal dysfunction, high pulmonary artery pressures, poor left ventricular function, hyponatremia, age, and simultaneous HIV and tuberculous infection.

Indexed as

Cardiac TamponadePericardial EffusionPericarditisAcute DiseaseAnti-Inflammatory Agents, Non-SteroidalBiopsyColchicineDiagnosis, DifferentialHumansPericardiectomyPericardiocentesisPericardiumPrognosisRecurrenceRisk FactorsSyndromeAnti-Inflammatory Agents, Non-SteroidalColchicineTubulin Modulators

Identifiers

PMID22855353
OpenAlexW2074935350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.